home / stock / xvipf / xvipf quote
Last: | $48.204 |
---|---|
Change Percent: | 0.0% |
Open: | $48.204 |
Close: | $48.204 |
High: | $48.204 |
Low: | $48.204 |
Volume: | 250 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$48.204 | $48.204 | $48.204 | $48.204 | $48.204 | 250 | 07-16-2024 |
$48.45 | $48.45 | $48.45 | $48.45 | $48.45 | 240 | 07-15-2024 |
$47.85 | $47.12 | $47.85 | $48.04 | $47.12 | 591 | 07-12-2024 |
$39.626 | $39.39 | $39.626 | $39.626 | $39.39 | 505 | 07-11-2024 |
$39.34 | $39.34 | $39.34 | $39.34 | $39.34 | 101 | 07-10-2024 |
$39.95 | $0 | $39.95 | $0 | $0 | 47 | 07-09-2024 |
$39.95 | $39.95 | $39.95 | $39.95 | $39.95 | 100 | 07-08-2024 |
$38.85 | $38.85 | $38.85 | $38.85 | $38.85 | 129 | 07-05-2024 |
$38.24 | $0 | $38.24 | $0 | $0 | 15 | 07-03-2024 |
$38.24 | $38.24 | $38.24 | $38.24 | $38.24 | 350 | 07-02-2024 |
$42.76 | $0 | $42.76 | $0 | $0 | 3 | 06-17-2024 |
$42.76 | $0 | $42.76 | $0 | $0 | 290 | 06-14-2024 |
$42.76 | $42.76 | $42.76 | $42.76 | $42.76 | 177 | 06-13-2024 |
$43.09 | $0 | $43.09 | $0 | $0 | 73 | 06-10-2024 |
$43.09 | $43.11 | $43.09 | $43.11 | $43.09 | 733 | 06-07-2024 |
$41.77 | $41.77 | $41.77 | $41.77 | $41.77 | 100 | 05-31-2024 |
$39.37 | $39.37 | $39.37 | $39.37 | $39.37 | 100 | 05-29-2024 |
$37.02 | $37.02 | $37.02 | $37.02 | $37.02 | 210 | 05-28-2024 |
$37.86 | $0 | $37.86 | $0 | $0 | 46 | 05-22-2024 |
$37.86 | $37.77 | $37.86 | $37.86 | $37.77 | 233 | 05-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Xvivo Perfusion Ab Ord Company Name:
XVIPF Stock Symbol:
OTCMKTS Market:
GOTHENBURG, SWEDEN / ACCESSWIRE / July 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Second quarter 2024 (Apr 1 - Jun 30) • Net sales amounted to SEK 210.3 million (154.6), corresponding to growth of 36 percent in SEK and 35 percent in local currencies. Organic growth a...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) First quarter 2024 (Jan 1 - Mar 31) • Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted ...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO's clinical trial, NIHP2019, in heart transplantation were pres...